PMA device
Freestyle Libre Pro
Abbott Diabetes Care, Inc. · Sensor, Glucose, Invasive, Non-Adjunctive, Factory-Calibrated, User-Initiated (PZE, Class III) · First FDA decision Dec 21, 2018, newest Apr 5, 2019Diabetes
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
PMA pathway
Device trials
38
Naming "Freestyle Libre Pro"
MAUDE reports
49
Brand "Freestyle Libre Pro", since 2015
PubMed studies
111
Mentioning "Freestyle Libre Pro"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Freestyle Libre Pro
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 2 of 2 decisions filed under this name.
- Freestyle Libre ProPMA supplement
P160030-S028 · Decided Apr 5, 2019 · 156 days after receipt · Normal 180 Day Track
Device type: Sensor, glucose, invasive, non-adjunctive, factory-calibrated, user-initiated (PZE) · Laboratory Medicine & Pathology
- Freestyle Libre ProPMA supplement
P160030-S027 · Decided Dec 21, 2018 · 85 days after receipt · Normal 180 Day Track
Device type: Sensor, glucose, invasive, non-adjunctive, factory-calibrated, user-initiated (PZE) · Laboratory Medicine & Pathology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Freestyle Libre Pro", any status and sponsor, newest update first.
- Glucose Pattern in Infertile Women Receiving Assisted Reproduction Using Continuous Glucose MonitoringActive, not recruiting
Shanghai 6th People's HospitalAcademic, hospital or other
NCT06863337 · 100 participants (planned) · Start Mar 26, 2025 · Primary completion Jun 30, 2026
Device: CGM · For: Infertility Female
Sites: Shanghai, China
- CGM in Acute Ischemic StrokeRecruiting
IsalaAcademic, hospital or other
NCT07510919 · 82 participants (planned) · Start Apr 21, 2026 · Primary completion May 2028
Device: Continuous Glucose Monitoring · For: Acute Ischemic Stroke; Diabetes (DM); Diabetes Type 2 and 2 more
Sites: Enschede, Netherlands; Zwolle, Netherlands
- Diabetes in African YouthPivotal-lookingActive, not recruiting
University of MinnesotaAcademic, hospital or other
NCT05454176 · 188 participants · Start Aug 15, 2022 · Primary completion Aug 15, 2027
Device: Libre 2; Device for SMBG and Libre Pro · For: type1diabetes
Sites: Minneapolis, Minnesota
35 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Freestyle Libre Pro", and for the whole product code for context.
This brand
49 reports: 15 malfunction, 34 injury, 0 death
Whole product code PZE
143,343 reports: 125,788 malfunction, 17,533 injury, 14 death
Newest reports for this brand
- FreeStyle Libre ProMalfunction
2954323-2026-425066 · Received Sep 21, 2026 · Event dated Jan 10, 2024
Device type: Sensor, Glucose, Invasive (MDS)
Device problem as coded: Incorrect, Inadequate or Imprecise Result or Readings
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
- FreeStyle Libre ProMalfunction
2954323-2026-403930 · Received Sep 10, 2026 · Event dated Jan 19, 2024
Device type: Sensor, Glucose, Invasive (MDS)
Device problem as coded: Detachment of Device or Device Component
Patient problem as coded: Device Embedded In Tissue or Plaque
- FreeStyle Libre ProMalfunction
2954323-2026-391389 · Received Sep 9, 2026 · Event dated Aug 30, 2024
Device type: Sensor, Glucose, Invasive (MDS)
Device problem as coded: Detachment of Device or Device Component
Patient problem as coded: Device Embedded In Tissue or Plaque
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
- FreeStyle Libre Reader, REF: 71525-01, 71701-01, 71739-01 a component of the FreeStyle Libre Flash Glucose Monitoring SystemOpen, Classified
Z-1273-2023 · Started Feb 13, 2023 · Posted by FDA Apr 6, 2023
Reason given: Lithium-ion batteries in glucose monitoring system readers may swell, overheat, or pose fire hazard. Only use the charging cable/power adapter included with readers. Do not use reader if it is damaged, cracked, swelling, too hot to hold, it will no longer hold charge, or it fails Reader Test. Do not use other...
Cause as FDA categorized it: Device Design · Device type: Sensor, Glucose, Invasive, Non-Adjunctive, Factory-Calibrated, User-Initiated (PZE)
Published research
The most relevant PubMed records for "Freestyle Libre Pro"[tiab]. The summary above synthesizes these.
- Continuous glucose monitoring with FreeStyle Libre PRO sensor in patients with type 2 diabetes and end-stage renal failure on haemoDIALysis (FSLPRO-DIAL pilot study).
Henry Z, Villar E, Chauvet C, et al. · Acta Diabetol · 2024
- Skin reactions to Freestyle Libre Pro among individuals with and without diabetes.
Rama Chandran S, Choo KJL, Tan HC, et al. · Diabet Med · 2025Letter
- Comparison of Accuracy of Freestyle Libre Pro and Medtronic iPro2 Continuous Glucose Monitoring Systems in Pregnancy.
Golla KK, Gupta Y, Goyal A, et al. · Diabetes Technol Ther · 2023Observational Study
- The Performance of Freestyle Libre Pro Flash Continuous Glucose Monitoring in Hospitalized Patients Treated with an Intravenous Insulin Infusion for Acute Prednisolone-Induced Hyperglycemia.
Chen AX, Radhakutty A, Zimmermann A, et al. · Diabetes Technol Ther · 2024
- Comparison of the FreeStyle Libre Pro Flash Continuous Glucose Monitoring (CGM) System and Point-of-Care Capillary Glucose Testing in Hospitalized Patients With Type 2 Diabetes Treated With Basal-Bolus Insulin Regimen.
Galindo RJ, Migdal AL, Davis GM, et al. · Diabetes Care · 2020Research Support, Non-U.S. Gov't, Comment
- Glucose variability in 6-12-month-old healthy infants.
Hauschild M, Monnard C, Eldridge AL, et al. · Front Nutr · 2023
- Breaking through diabetes management barriers: Assessing the accuracy of Freestyle Libre Pro flash continuous glucose monitoring in diabetes patients with myocardial infarction.
Shen L, Xu L, Zhang C, et al. · Digit Health · 2024
- Comparison of glucose monitoring between Freestyle Libre Pro and iPro2 in patients with diabetes mellitus.
Kumagai R, Muramatsu A, Fujii M, et al. · J Diabetes Investig · 2019Comparative Study
- Continuous glucose monitoring using the FreeStyle Libre Pro iQ in presymptomatic type 1 diabetes.
Weiss A, Huber E, Reinmüller F, et al. · Diabetologia · 2026
- Continuous glucose monitoring to characterize hyperglycemia during chemotherapy for early stage breast cancer.
Ulene SR, Wang S, Cook JR, et al. · Breast Cancer Res Treat · 2025Observational Study
- Responses of Driver-Athletes to Repeated Driving Stints.
Potkanowicz ES, Ferguson DP, Greenshields JT · Med Sci Sports Exerc · 2021
- Ambulatory glucose profile in diabetes-related dementia.
Ogawa Y, Shimizu S, Takenoshita N, et al. · Geriatr Gerontol Int · 2019
Other devices of this type
Also filed under product code PZE.
- FreeStyle Libre 14 day Flash Glucose Monitoring SystemAbbott Diabetes Care, Inc. · PMA 2024
- Freestyle Libre Flash Glucose Monitoring SystemAbbott Diabetes Care, Inc. · PMA 2019
- FreeStyle Libre 14-day Flash Glucose Monitoring SystemAbbott Diabetes Care, Inc. · PMA 2023
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.